AbbVie Inc

ABBV

New York Stock Exchange. Currency in USD

161.63 +0.45 ( +0.28% )

Real time prices: December 01

Market Cap.
285.84B
Beta (5Y monthly)
0.66
Price/Earnings
11.81
EPS (TTM)
13.50
Forward Dividend
5.92 (3.74%)
Ex-Dividend Date
Jan 13, 2023
Volume
5.83M
1y Target Est.
159.44
Day's Range
159.98
-
163.20
52 Week's Range
117.00
-
175.91

Historical Summary

Performance
EPS growth
Share Buybacks

About AbbVie Inc

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.abbvie.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
1.77B
Employees
50000
Address
1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Latest news

Why Is Pfizer (PFE) Up 6.5% Since Last Earnings Report?
Why Is Pfizer (PFE) Up 6.5% Since Last Earnings Report?

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a...
By Zacks Investment Research - 16 hours ago

S&P 500's Best Dividend Aristocrats
S&P 500's Best Dividend Aristocrats

Investors looking for stability and payout growth should look closer at Dividend Aristocrat stocks.
By The Motley Fool - 1 day ago

3 Top Dividend Kings to Buy for the Long Haul
3 Top Dividend Kings to Buy for the Long Haul

Dividend stocks are an easy option to boost income.
By The Motley Fool - 1 day ago

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

Smart Beta ETF report for HDV
By Zacks Investment Research - 1 day ago

2 High Income ETFs Crushing the S&P 500
2 High Income ETFs Crushing the S&P 500

These ETFs use option strategies to generate juicy income & lower portfolio volatility
By Zacks Investment Research - 2 days ago

3 Reasons Pfizer Stock Will Crush the Broader Market in 2023
3 Reasons Pfizer Stock Will Crush the Broader Market in 2023

Pfizer's revenue growth is far from over.
By The Motley Fool - 2 days ago

Here's What's Driving AbbVie's (ABBV) Outperformance This Year
Here's What's Driving AbbVie's (ABBV) Outperformance This Year

AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses...
By Zacks Investment Research - 3 days ago

8 Dividend Aristocrats to Buy Now for a Lifetime of Passive Income
8 Dividend Aristocrats to Buy Now for a Lifetime of Passive Income

Dividend stocks are a great way to protect against a downturn and these are the...
By The Motley Fool - 4 days ago